These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 7948106)

  • 41. Inhibition of metabolic activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone by limonene.
    Morse MA; Toburen AL
    Cancer Lett; 1996 Jul; 104(2):211-7. PubMed ID: 8665490
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inhibition of DMBA-induced mammary cancer by the monoterpene d-limonene.
    Elegbede JA; Elson CE; Qureshi A; Tanner MA; Gould MN
    Carcinogenesis; 1984 May; 5(5):661-4. PubMed ID: 6426810
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Involvement of YY1 and its correlation with c-myc in NDEA induced hepatocarcinogenesis, its prevention by d-limonene.
    Parija T; Das BR
    Mol Biol Rep; 2003 Mar; 30(1):41-6. PubMed ID: 12688534
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effectiveness of combined limonene and 4-hydroxyandrostenedione in the treatment of NMU-induced rat mammary tumours.
    Chander SK; Lansdown AG; Luqmani YA; Gomm JJ; Coope RC; Gould N; Coombes RC
    Br J Cancer; 1994 May; 69(5):879-82. PubMed ID: 8180018
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of 1,4-phenylenebis(methylene)selenocyanate, phenethyl isothiocyanate, indole-3-carbinol, and d-limonene individually and in combination on the tumorigenicity of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in A/J mouse lung.
    el-Bayoumy K; Upadhyaya P; Desai DH; Amin S; Hoffmann D; Wynder EL
    Anticancer Res; 1996; 16(5A):2709-12. PubMed ID: 8917375
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee.
    Vigushin DM; Poon GK; Boddy A; English J; Halbert GW; Pagonis C; Jarman M; Coombes RC
    Cancer Chemother Pharmacol; 1998; 42(2):111-7. PubMed ID: 9654110
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Plasma metabolomic profiles of breast cancer patients after short-term limonene intervention.
    Miller JA; Pappan K; Thompson PA; Want EJ; Siskos AP; Keun HC; Wulff J; Hu C; Lang JE; Chow HH
    Cancer Prev Res (Phila); 2015 Jan; 8(1):86-93. PubMed ID: 25388013
    [TBL] [Abstract][Full Text] [Related]  

  • 48. D-limonene suppresses doxorubicin-induced oxidative stress and inflammation via repression of COX-2, iNOS, and NFκB in kidneys of Wistar rats.
    Rehman MU; Tahir M; Khan AQ; Khan R; Oday-O-Hamiza ; Lateef A; Hassan SK; Rashid S; Ali N; Zeeshan M; Sultana S
    Exp Biol Med (Maywood); 2014 Apr; 239(4):465-76. PubMed ID: 24586096
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chemoprevention of spontaneous tumorigenesis in p53-knockout mice.
    Hursting SD; Perkins SN; Haines DC; Ward JM; Phang JM
    Cancer Res; 1995 Sep; 55(18):3949-53. PubMed ID: 7664260
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Isoprenylation of proteins in the protozoan Giardia lamblia.
    Luján HD; Mowatt MR; Chen GZ; Nash TE
    Mol Biochem Parasitol; 1995 Jun; 72(1-2):121-7. PubMed ID: 8538683
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identifying differential gene expression in monoterpene-treated mammary carcinomas using subtractive display.
    Ariazi EA; Gould MN
    J Biol Chem; 1996 Nov; 271(46):29286-94. PubMed ID: 8910589
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of chemopreventive agents against breast cancer and proposed strategies for future clinical intervention trials.
    el-Bayoumy K
    Carcinogenesis; 1994 Nov; 15(11):2395-420. PubMed ID: 7955084
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Limonene arrests parasite development and inhibits isoprenylation of proteins in Plasmodium falciparum.
    Moura IC; Wunderlich G; Uhrig ML; Couto AS; Peres VJ; Katzin AM; Kimura EA
    Antimicrob Agents Chemother; 2001 Sep; 45(9):2553-8. PubMed ID: 11502528
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Regression of rat primary mammary tumors following dietary d-limonene.
    Elegbede JA; Elson CE; Tanner MA; Qureshi A; Gould MN
    J Natl Cancer Inst; 1986 Feb; 76(2):323-5. PubMed ID: 3080636
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prenylated proteins and lymphocyte proliferation: inhibition by d-limonene related monoterpenes.
    Schulz S; Bühling F; Ansorge S
    Eur J Immunol; 1994 Feb; 24(2):301-7. PubMed ID: 8299679
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of NNK-induced lung tumorigenesis by modulators of NNK activation.
    Morse MA
    Exp Lung Res; 1998; 24(4):595-604. PubMed ID: 9659585
    [TBL] [Abstract][Full Text] [Related]  

  • 57. D-limonene: A multifunctional compound with potent therapeutic effects.
    Anandakumar P; Kamaraj S; Vanitha MK
    J Food Biochem; 2021 Jan; 45(1):e13566. PubMed ID: 33289132
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of dietary supplementation with limonene or myo-inositol on the induction of neoplasia and matrix metalloproteinase and plasminogen activator activities in accessory sex organs of male Lobund-Wistar rats.
    Wilson MJ; Lindgren BR; Sinha AA
    Exp Mol Pathol; 2008 Oct; 85(2):83-9. PubMed ID: 18675799
    [TBL] [Abstract][Full Text] [Related]  

  • 59. d-limonene, an anticarcinogenic terpene.
    Nutr Rev; 1988 Oct; 46(10):363-5. PubMed ID: 3067145
    [No Abstract]   [Full Text] [Related]  

  • 60. Risk assessment of d-limonene: an example of male rat-specific renal tumorigens.
    Hard GC; Whysner J
    Crit Rev Toxicol; 1994; 24(3):231-54. PubMed ID: 7945892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.